KSHV QTV · Identification of novel KSHV immune evasion mechanisms using a quantitative temporal viromics analysis
Horizon 2020 — Marie Skłodowska-Curie Actions
- Duration
- 2015-06-15 → 2017-06-14
- EU contribution
- €183,455
- Participants
- 1
- Scheme
- MSCA-IF-EF-ST
Lines connect the coordinator with its partners.
Results in brief
Identification of novel KSHV immune evasion mechanisms using a quantitative temporal viromics analysis
Kaposi’s Sarcoma-associated herpesvirus (KSHV) is the causative agent of Kaposi’s sarcoma and two B cell malignancies: primary effusion lymphoma and multicentric Castelman’s disease. Kaposi’s Sarcoma is a tumour of endothelial cells which is inactive in subjects with healthy immune system, but disseminates as an aggressive tumour in immunosuppressed e.g. HIV-infected individuals, particularly affecting the lungs and gastrointestinal tract. In fact, Kaposi’s Sarcoma is one of the commonest tumours of AIDS patients, with an often fatal outcome. The number of KSHV-seropositive individuals varies depending on geographical location, with a maximum of more than 50% in sub-Saharan Africa, where Kaposi’s Sarcoma is the second largest contributor to the cancer burden (Plummer, Lancet 2016). Investigation of the molecular mechanisms of KSHV infection will contribute to our knowledge on KSHV pathogenesis and may open new perspectives for therapeutic treatment of KSHV-associated malignancies. KSHV manipulates its host cell environment to enable replication and evade the host immune response, but these changes have been predominantly analysed at the transcriptional level. Changes in mRNA may not accurately reflect changes in cellular proteins, nor do they reflect the post-translational changes (such as degradation) induced by viral infection. How KSHV infection alters cellular proteins has only been analysed at the individual protein level or through proteomic studies of individual viral genes e.g. K5. During lytic stage infection, KSHV mediates degradation of several host proteins, including adhesion molecules, immune receptors, transcription and restriction factors, but an unbiased systematic analysis of the KSHV-induced changes in the host cell proteome is lacking. Therefore, the goal of this study was to perform a quantitative proteomics analysis of KSHV-infected cells to unravel virus-induced changes in host cells and determine how these changes impact the host immune system. The objectives of this project were to: (1) establish a KSHV reactivation model in human endothelial cells, a physiologically relevant cell type for KSHV infection; (2) apply systematic and unbiased approaches to resolve changes in both the host and viral proteomes in endothelial cells upon KSHV reactivation; (3) identify host molecules modulated (i.e. degraded) by KSHV and (4) investigate these novel aspects of virus-host interaction.
Data: CORDIS, © European Union
Project objective
Kaposi’s Sarcoma-associated herpesvirus, or human herpesvirus 8, is an important cause of morbidity and mortality, causing tumors in immunosuppressed patients, in particular those with AIDS. Like other herpesviruses, KSHV has evolved numerous mechanisms of escape from both the innate and adaptive host immune response. These immune evasion strategies facilitate the virus’s oncogenic potential and contribute to its pathogenesis. Beyond immune modulation, many viral proteins interact with components of the cellular proteome to enable viral replication. However, the complete array of such proteins, their kinetics and fate in both latent and lytic phase of viral infection has never been determined. Here, I propose an unbiased proteomic approach to analyze the expression kinetics of the KSHV proteome in the context of cellular infection, and explore how host cell surface and cytoplasmic proteins are regulated by this virus throughout its infection cycle. To achieve this goal I will resolve both the host cell and the viral proteome in primary endothelial cells and B cells using the recently developed technique, quantitative temporal viromics. This novel approach is interdisciplinary, incorporating virology, immunology, cell biology, state-of-the-art proteomics and has been successfully applied to identify novel markers of latent HCMV infection as well as novel immunomodulation strategies. The proposed study will allow a temporal analysis of how the host and viral proteome change upon latent as well as lytic KSHV infection. Newly discovered viral targets, such as ligands for Natural killer (NK) or cytotoxic T cells will be validated and investigated using biochemical and virological methods available in the host (Lehner) lab. The results of this study will therefore provide unique insight into the virus-host interactions and uncover novel viral strategies of the host immune system. The identified proteins may ultimately serve as novel targets for therapeutic interventions.
Original text from CORDIS.
Participants
- THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE · CAMBRIDGECoordinatorUnited Kingdom
Links
- View on CORDIS
- DOI: 10.3030/656511
- https://web.archive.org/web/20170221090856/https://www.cimr.cam.ac.uk/research/principal-investigators/principal-investigators-i-p/lehner
- https://www.cimr.cam.ac.uk/research/principal-investigators/principal-investigators-i-p/lehner
Data: CORDIS, © European Union
